PRS-080#022-DP

BIOLOGICAL3 trials

Sponsors

Pieris Pharmaceuticals GmbH

Conditions

Anemia of Chronic Kidney DiseaseHealthy

Phase 1

First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PRS-080

CompletedNCT02340572

Pieris Pharmaceuticals GmbHHealthy

Start: 2014-11-30End: 2015-08-31Updated: 2015-08-10

Phase Ib Study to Evaluate PRS-080 in Anemic Chronic Kidney Disease Patients

Pieris Pharmaceuticals GmbHAnemia of Chronic Kidney Disease

Start: 2016-06-06End: 2017-12-31Updated: 2017-10-20

Phase 2a Study to Evaluate PRS-080 in Anemic Chronic Kidney Disease Patients

CompletedNCT03325621

Pieris Pharmaceuticals GmbHAnemia of Chronic Kidney Disease

Start: 2017-09-30End: 2019-06-30Updated: 2019-10-21

Related Papers

A Phase I Study Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of the Hepcidin Antagonist PRS-080#022. Results from a Randomized, Placebo Controlled, Double-Blind Study Following Single Administration to Healthy Subjectsa

Blood2015-12-0314 citations